Brief: I-Mab Announces Completion Of Patient Enrollment In Phase III Clinical Trial Of Eftansomatropin Alfa
31/05/2022 13:01
May 31 (Reuters) - I-Mab IMAB.O :
* I-MAB ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE
III
CLINICAL TRIAL OF EFTANSOMATROPIN ALFA FOR TREATMENT OF
PEDIATRIC GROWTH HORMONE DEFICIENCY
Source text for Eikon: ID:nPn8Df096a
Further company coverage: IMAB.O
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview